Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D-Ligand Targeted CAR-NK Cells in Metastatic Solid Tumours
NCT03415100Phase 1Unknown
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in solid tumor, sponsored by The Third Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Number of Adverse Events at 4 months. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03415100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415100.